<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02275780</url>
  </required_header>
  <id_info>
    <org_study_id>1439-018</org_study_id>
    <secondary_id>2014-001127-69</secondary_id>
    <secondary_id>MK-1439-018</secondary_id>
    <nct_id>NCT02275780</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1) (MK-1439-018)</brief_title>
  <acronym>DRIVE-FORWARD</acronym>
  <official_title>A Phase 3 Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Doravirine (MK-1439) 100 mg Once Daily Versus Darunavir 800 mg Once Daily Plus Ritonavir 100 mg Once Daily, Each in Combination With TRUVADA™ or EPZICOM™/KIVEXA™, in Treatment-Naïve HIV-1 Infected Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To establish a new treatment option for treatment-naïve participants with HIV-1, the efficacy
      and safety of doravirine will be determined relative to a protease inhibitor (PI).
      Participants will receive double-blind treatment during the 96-week Base Study. Eligible
      participants in either of the Base Study groups will continue to receive the
      doravirine-containing regimen open label for an additional 96 weeks in the Study Extension 1.
      Eligible participants who are deriving benefit will continue in Study Extension 2 to receive
      the doravirine-containing regimen open label until doravirine becomes locally available or
      for an additional 96 weeks, whichever comes first. The primary hypothesis is that doravirine
      100 mg once a day (q.d.) is non-inferior to darunavir/ritonavir (800 mg/100 mg) q.d., each in
      combination with TRUVADA™ or EPZICOM™/KIVEXA™, as assessed by the proportion of participants
      with HIV-1 ribonucleic acid (RNA) &lt;50 copies/mL at Week 48. If non-inferiority is
      established, then the superiority of doravirine 100 mg q.d. compared to darunavir/ ritonavir
      (800 mg/100 mg) q.d. will be assessed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants in Australia, Russia, and South Africa who are deriving benefit from MK-1439A
      are also eligible to continue receiving study drug during Study Extension 3, which will last
      for 2 years or until drug is available locally, whichever comes first.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 1, 2014</start_date>
  <completion_date type="Anticipated">June 23, 2021</completion_date>
  <primary_completion_date type="Actual">September 29, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Plasma HIV-1 RNA &lt;50 Copies/mL at Week 48</measure>
    <time_frame>Week 48</time_frame>
    <description>The percentage of participants in each arm achieving HIV-1 RNA levels &lt;50 copies/mL at Week 48 was determined. Plasma HIV-1 RNA levels were quantified with the Abbott RealTime HIV-1 Assay. Data were handled according to the US Food and Drug Administration (FDA) &quot;snapshot&quot; approach and all missing data were considered treatment failures, regardless of the reason.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Plasma HIV-1 RNA &lt;50 Copies/mL at Week 96</measure>
    <time_frame>Week 96</time_frame>
    <description>The percentage of participants in each arm achieving HIV-1 RNA levels &lt;50 copies/mL at Week 96 was determined. Plasma HIV-1 RNA levels were quantified with the Abbott RealTime HIV-1 Assay. Data were handled according to the US Food and Drug Administration (FDA) &quot;snapshot&quot; approach and all missing data were considered treatment failures, regardless of the reason.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean CD4+ T-cell Count at Week 48</measure>
    <time_frame>Baseline and Week 48</time_frame>
    <description>CD4+ T-cell counts were quantified by a central laboratory using a commercially available assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean CD4+ T-cell Count at Week 96</measure>
    <time_frame>Baseline and Week 96</time_frame>
    <description>CD4+ T-cell counts were quantified by a central laboratory using a commercially available assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) at Week 48</measure>
    <time_frame>Baseline and Week 48</time_frame>
    <description>Serum LDL-C was determined after an overnight fast. Change from Baseline was analyzed using ANCOVA models with terms for Baseline lipid level and treatment group. The Last Observation Carry Forward (LOCF) approach was applied for missing data or data collected after modifying lipid-lowering therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Fasting Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 48</measure>
    <time_frame>Baseline and Week 48</time_frame>
    <description>Serum non-HDL-C was determined after an overnight fast. Change from Baseline was analyzed using ANCOVA models with terms for Baseline lipid level and treatment group. The LOCF approach was applied for missing data or data collected after modifying lipid-lowering therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Fasting High Density Lipoprotein Cholesterol (HDL-C) at Week 48</measure>
    <time_frame>Baseline and Week 48</time_frame>
    <description>Serum HDL-C was determined after an overnight fast. Change from Baseline was analyzed using ANCOVA models with terms for Baseline lipid level and treatment group. The LOCF approach was applied for missing data or data collected after modifying lipid-lowering therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Fasting Total Cholesterol at Week 48</measure>
    <time_frame>Baseline and Week 48</time_frame>
    <description>Serum total cholesterol was determined after an overnight fast. Change from Baseline was analyzed using ANCOVA models with terms for Baseline lipid level and treatment group. The LOCF approach was applied for missing data or data collected after modifying lipid-lowering therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Fasting Triglyceride at Week 48</measure>
    <time_frame>Baseline and Week 48</time_frame>
    <description>Serum triglyceride was determined after an overnight fast. Change from Baseline was analyzed using ANCOVA models with terms for Baseline lipid level and treatment group. The LOCF approach was applied for missing data or data collected after modifying lipid-lowering therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Any Adverse Event</measure>
    <time_frame>Up to 98 weeks</time_frame>
    <description>An adverse event (AE) is defined as any untoward medical occurrence in a study participant and which does not necessarily have to have a causal relationship to treatment. An adverse event can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the study treatment or protocol-specified procedure, whether or not considered related to study treatment or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the study treatment is also an AE. The percentage of participants with any AE was assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Any Serious Adverse Event</measure>
    <time_frame>Up to 98 weeks</time_frame>
    <description>A serious adverse event is an AE that results in death, is life threatening, results in persistent or significant disability or incapacity, results in or prolongs a hospitalization, is a congenital anomaly or birth defect, is a cancer, is associated with an overdose, or is another important medical event. The percentage of participants with any SAE was assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Any Drug-related Adverse Event</measure>
    <time_frame>Up to 98 weeks</time_frame>
    <description>The investigator was to determine if an AE had a reasonable possibility of a relationship to the study drug. The percentage of participants with any drug-related AE was assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Any Drug-related Serious Adverse Event</measure>
    <time_frame>Up to 98 weeks</time_frame>
    <description>The percentage of participants with any drug-related SAE was assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Discontinued Study Treatment Due to an Adverse Event</measure>
    <time_frame>Up to 96 weeks</time_frame>
    <description>The percentage of participants who discontinued study treatment due to an AE was assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Plasma HIV-1 RNA &lt;40 Copies/mL at Week 48</measure>
    <time_frame>Week 48</time_frame>
    <description>The percentage of participants in each arm achieving HIV-1 RNA levels &lt;40 copies/mL at Week 48 was determined. Plasma HIV-1 RNA levels were quantified with the Abbott RealTime HIV-1 Assay. Data were handled according to the US Food and Drug Administration (FDA) &quot;snapshot&quot; approach and all missing data were considered treatment failures, regardless of the reason.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Plasma HIV-1 RNA &lt;40 Copies/mL at Week 96</measure>
    <time_frame>Week 96</time_frame>
    <description>The percentage of participants in each arm achieving HIV-1 RNA levels &lt;40 copies/mL at Week 96 was determined. Plasma HIV-1 RNA levels were quantified with the Abbott RealTime HIV-1 Assay. Data were handled according to the US Food and Drug Administration (FDA) &quot;snapshot&quot; approach and all missing data were considered treatment failures, regardless of the reason.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">769</enrollment>
  <condition>HIV-1</condition>
  <arm_group>
    <arm_group_label>Doravirine 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Double-blind Doravirine 100 mg administered orally (p.o.) once daily (q.d.) + investigator selected TRUVADA™ or EPZICOM™/KIVEXA™ administered p.o., q.d. for 96 weeks in the Base Study. Eligible participants may continue in Study Extension 1 with open-label Doravirine 100 mg administered p.o., q.d. + investigator selected TRUVADA™ or EPZICOM™/KIVEXA™ administered p.o., q.d. for an additional 96 weeks. Eligible participants may continue to receive the same treatment regimen in Study Extension 2 until doravirine becomes locally available, or for an additional 96 weeks, whichever comes first.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Darunavir 800 mg and Ritonavir 100 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Double-blind Darunavir 800 mg and Ritonavir 100 mg administered p.o., q.d. + investigator selected TRUVADA™ or EPZICOM™/KIVEXA™ administered p.o., q.d. for 96 weeks. Eligible participants may continue in Study Extension 1 with open-label Doravirine 100 mg administered p.o., q.d. + investigator selected TRUVADA™ or EPZICOM™/KIVEXA™ administered p.o., q.d. for an additional 96 weeks. Eligible participants may continue to receive the same treatment regimen in Study Extension 2 until doravirine becomes locally available, or for an additional 96 weeks, whichever comes first.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doravirine</intervention_name>
    <description>Doravirine 100 mg tablet administered p.o., q.d.</description>
    <arm_group_label>Darunavir 800 mg and Ritonavir 100 mg</arm_group_label>
    <arm_group_label>Doravirine 100 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darunavir</intervention_name>
    <description>Darunavir 800 mg tablet administered p.o., q.d.</description>
    <arm_group_label>Darunavir 800 mg and Ritonavir 100 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir</intervention_name>
    <description>Ritonavir 100 mg tablet administered p.o., q.d.</description>
    <arm_group_label>Darunavir 800 mg and Ritonavir 100 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TRUVADA™ or EPZICOM™/KIVEXA™</intervention_name>
    <description>The investigator selects either TRUVADA™, a tablet containing 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate, p.o., q.d., or EPZICOM™/KIVEXA™, a tablet containing 600 mg abacavir sulfate and 300 mg lamivudine, p.o., q.d.</description>
    <arm_group_label>Darunavir 800 mg and Ritonavir 100 mg</arm_group_label>
    <arm_group_label>Doravirine 100 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Is HIV-1 positive and has HIV treatment indicated based on physician assessment.

          -  Has received no (0 days of) antiretroviral therapy (ART), including investigational
             antiretroviral agents.

          -  Is considered clinically stable with no signs or symptoms of active infection for at
             least 2 weeks prior to the start of treatment.

          -  Female is highly unlikely to become pregnant, or male is highly unlikely to impregnate
             a partner because they are not of reproductive potential, or agree to practice
             abstinence or use acceptable contraception for up to 14 days after the last dose of
             study drug.

          -  Eligibility for the Study Extension 1 at the Week 96 visit: 1) completed the Week 96
             visit, 2) derived benefit from participation through Week 96 in the opinion of the
             investigator, 3) is a clinically-appropriate candidate for an additional 96 weeks of
             treatment with the Study Extension regimen.

          -  Eligibility for the Study Extension 2 at the Week 192 visit: 1) completed the Week 192
             visit, 2) derived benefit from participation through Week 192 in the opinion of the
             investigator, 3) is a clinically-appropriate candidate for 96 weeks of treatment with
             the Study Extension regimen.

        Exclusion Criteria:

          -  Uses or has had a recent history of using recreational or illicit drugs.

          -  Has been treated for a viral infection other than HIV-1, such as hepatitis B, with an
             agent that is active against HIV-1.

          -  Has documented or known resistance to study drugs including doravirine, darunavir,
             ritonavir, emtricitabine, tenofovir, abacavir and/or lamivudine.

          -  Has participated in a study with an investigational compound/device within the prior
             month, or anticipates doing so during this study.

          -  Has used systemic immunosuppressive therapy or immune modulators within the prior 30
             days, or anticipates doing so during this study.

          -  Has significant hypersensitivity or other contraindication to any of the components of
             the study drugs.

          -  Has a current (active) diagnosis of acute hepatitis due to any cause.

          -  Is pregnant, breastfeeding or expecting to conceive at any time during the study.

          -  Female who expects to donate eggs, or male who expects to donate sperm at any time
             during the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Puerto Rico</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>October 23, 2014</study_first_submitted>
  <study_first_submitted_qc>October 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2014</study_first_posted>
  <results_first_submitted>September 28, 2018</results_first_submitted>
  <results_first_submitted_qc>September 28, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 23, 2018</results_first_posted>
  <last_update_submitted>April 14, 2020</last_update_submitted>
  <last_update_submitted_qc>April 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Darunavir</mesh_term>
    <mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 1027 participants were screened and 769 were randomized. This report covers results for the 96-month Base Study. Results for the ongoing open-label study extensions will be reported when the extensions are completed.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Doravirine 100 mg</title>
          <description>Double-blind Doravirine 100 mg administered orally (p.o.) once daily (q.d.) + investigator-selected TRUVADA™ or EPZICOM™/KIVEXA™ administered p.o., q.d. for 96 weeks in the Base Study. Eligible participants may continue in Study Extension 1 with open-label Doravirine 100 mg administered p.o., q.d. + investigator-selected TRUVADA™ or EPZICOM™/ KIVEXA™ administered p.o., q.d. for an additional 96 weeks. Eligible participants may continue to receive the same treatment regimen in Study Extension 2 until doravirine becomes locally available, or for an additional 96 weeks, whichever comes first.</description>
        </group>
        <group group_id="P2">
          <title>Daurunavir 800 mg + Ritonavir 100 mg</title>
          <description>Double-blind Darunavir 800 mg and Ritonavir 100 mg administered p.o., q.d. + investigator-selected TRUVADA™ or EPZICOM™/ KIVEXA™ administered p.o., q.d. for 96 weeks. Eligible participants may continue in Study Extension 1 with open-label Doravirine 100 mg administered p.o., q.d. + investigator-selected TRUVADA™ or EPZICOM™/ KIVEXA™ administered p.o., q.d. for an additional 96 weeks. Eligible participants may continue to receive the same treatment regimen in Study Extension 2 until doravirine becomes locally available, or for an additional 96 weeks, whichever comes first.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Base Study: 96 Weeks</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="385"/>
                <participants group_id="P2" count="384"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="383"/>
                <participants group_id="P2" count="383"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="292"/>
                <participants group_id="P2" count="273"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="93"/>
                <participants group_id="P2" count="111"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliance with drug</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized not treated</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Extension Study: up to 192 Weeks</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="260">The extension study is optional; not all eligible participants enrolled</participants>
                <participants group_id="P2" count="233">The extension study is optional; not all eligible participants enrolled</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0">The extension study is ongoing</participants>
                <participants group_id="P2" count="0">The extension study is ongoing</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="260"/>
                <participants group_id="P2" count="233"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Ongoing</title>
              <participants_list>
                <participants group_id="P1" count="260"/>
                <participants group_id="P2" count="233"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants who received at least 1 dose of study drug</population>
      <group_list>
        <group group_id="B1">
          <title>Doravirine 100 mg</title>
          <description>Double-blind Doravirine 100 mg administered orally (p.o.) once daily (q.d.) + investigator-selected TRUVADA™ or EPZICOM™/KIVEXA™ administered p.o., q.d. for 96 weeks in the Base Study.</description>
        </group>
        <group group_id="B2">
          <title>Daurunavir 800 mg + Ritonavir 100 mg</title>
          <description>Double-blind Darunavir 800 mg and Ritonavir 100 mg administered p.o., q.d. + investigator-selected TRUVADA™ or EPZICOM™/ KIVEXA™ administered p.o., q.d. for 96 weeks in the Base Study.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="383"/>
            <count group_id="B2" value="383"/>
            <count group_id="B3" value="766"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="383"/>
                    <count group_id="B2" value="383"/>
                    <count group_id="B3" value="766"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.8" spread="10.5"/>
                    <measurement group_id="B2" value="35.7" spread="10.7"/>
                    <measurement group_id="B3" value="35.2" spread="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="383"/>
                    <count group_id="B2" value="383"/>
                    <count group_id="B3" value="766"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="121"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="319"/>
                    <measurement group_id="B2" value="326"/>
                    <measurement group_id="B3" value="645"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean Cluster of Differentiation 4 (CD4+) T-cell Count</title>
          <description>CD4+ T-cell count was quantified by a central laboratory using a commercially available assay</description>
          <units>Cells/mm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="383"/>
                    <count group_id="B2" value="383"/>
                    <count group_id="B3" value="766"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="432.6" spread="208.4"/>
                    <measurement group_id="B2" value="411.9" spread="229.6"/>
                    <measurement group_id="B3" value="422.2" spread="219.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Plasma HIV-1 RNA</title>
          <description>Plasma HIV-1 RNA levels were quantified with the Abbott RealTime HIV-1 Assay</description>
          <population>All participants who received at least 1 dose of study drug and had Baseline data available</population>
          <units>Copies/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="383"/>
                    <count group_id="B2" value="382"/>
                    <count group_id="B3" value="765"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27073.0" lower_limit="105" upper_limit="2776658"/>
                    <measurement group_id="B2" value="27357.0" lower_limit="235" upper_limit="3272236"/>
                    <measurement group_id="B3" value="27073.0" lower_limit="105" upper_limit="3272236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving Plasma HIV-1 RNA &lt;50 Copies/mL at Week 48</title>
        <description>The percentage of participants in each arm achieving HIV-1 RNA levels &lt;50 copies/mL at Week 48 was determined. Plasma HIV-1 RNA levels were quantified with the Abbott RealTime HIV-1 Assay. Data were handled according to the US Food and Drug Administration (FDA) &quot;snapshot&quot; approach and all missing data were considered treatment failures, regardless of the reason.</description>
        <time_frame>Week 48</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Doravirine 100 mg</title>
            <description>Double-blind Doravirine 100 mg administered orally (p.o.) once daily (q.d.) + investigator-selected TRUVADA™ or EPZICOM™/KIVEXA™ administered p.o., q.d. for 96 weeks in the Base Study.</description>
          </group>
          <group group_id="O2">
            <title>Daurunavir 800 mg + Ritonavir 100 mg</title>
            <description>Double-blind Darunavir 800 mg and Ritonavir 100 mg administered p.o., q.d. + investigator-selected TRUVADA™ or EPZICOM™/ KIVEXA™ administered p.o., q.d. for 96 weeks in the Base Study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Plasma HIV-1 RNA &lt;50 Copies/mL at Week 48</title>
          <description>The percentage of participants in each arm achieving HIV-1 RNA levels &lt;50 copies/mL at Week 48 was determined. Plasma HIV-1 RNA levels were quantified with the Abbott RealTime HIV-1 Assay. Data were handled according to the US Food and Drug Administration (FDA) &quot;snapshot&quot; approach and all missing data were considered treatment failures, regardless of the reason.</description>
          <population>All randomized participants who received at least 1 dose of study drug</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="383"/>
                <count group_id="O2" value="383"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.8"/>
                    <measurement group_id="O2" value="79.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Doravirine is concluded to be non-inferior to darunavir + ritonavir if the lower bound of the 95% CI for the difference in percent response is above -10 percentage points.</non_inferiority_desc>
            <param_type>Treatment Difference</param_type>
            <param_value>3.913</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.590</ci_lower_limit>
            <ci_upper_limit>9.415</ci_upper_limit>
            <estimate_desc>Stratum-adjusted Mantel-Haenszel method with the difference weighted by the harmonic mean of sample size per arm for each stratum.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Plasma HIV-1 RNA &lt;50 Copies/mL at Week 96</title>
        <description>The percentage of participants in each arm achieving HIV-1 RNA levels &lt;50 copies/mL at Week 96 was determined. Plasma HIV-1 RNA levels were quantified with the Abbott RealTime HIV-1 Assay. Data were handled according to the US Food and Drug Administration (FDA) &quot;snapshot&quot; approach and all missing data were considered treatment failures, regardless of the reason.</description>
        <time_frame>Week 96</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug and had data for the outcome measure. Participants with missing HIV-1 RNA due to an Abbott RealTime manufacturing agent recall were excluded from the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Doravirine 100 mg</title>
            <description>Double-blind Doravirine 100 mg administered orally (p.o.) once daily (q.d.) + investigator-selected TRUVADA™ or EPZICOM™/KIVEXA™ administered p.o., q.d. for 96 weeks in the Base Study.</description>
          </group>
          <group group_id="O2">
            <title>Daurunavir 800 mg + Ritonavir 100 mg</title>
            <description>Double-blind Darunavir 800 mg and Ritonavir 100 mg administered p.o., q.d. + investigator-selected TRUVADA™ or EPZICOM™/ KIVEXA™ administered p.o., q.d. for 96 weeks in the Base Study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Plasma HIV-1 RNA &lt;50 Copies/mL at Week 96</title>
          <description>The percentage of participants in each arm achieving HIV-1 RNA levels &lt;50 copies/mL at Week 96 was determined. Plasma HIV-1 RNA levels were quantified with the Abbott RealTime HIV-1 Assay. Data were handled according to the US Food and Drug Administration (FDA) &quot;snapshot&quot; approach and all missing data were considered treatment failures, regardless of the reason.</description>
          <population>All randomized participants who received at least 1 dose of study drug and had data for the outcome measure. Participants with missing HIV-1 RNA due to an Abbott RealTime manufacturing agent recall were excluded from the analysis.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="379"/>
                <count group_id="O2" value="376"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.1"/>
                    <measurement group_id="O2" value="66.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Doravirine is concluded to be non-inferior to darunavir + ritonavir if the lower bound of the 95% CI for the difference in percent response is above -10 percentage points.</non_inferiority_desc>
            <param_type>Treatment Difference</param_type>
            <param_value>7.082</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.508</ci_lower_limit>
            <ci_upper_limit>13.656</ci_upper_limit>
            <estimate_desc>Stratum-adjusted Mantel-Haenszel method with the difference weighted by the harmonic mean of sample size per arm for each stratum.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean CD4+ T-cell Count at Week 48</title>
        <description>CD4+ T-cell counts were quantified by a central laboratory using a commercially available assay.</description>
        <time_frame>Baseline and Week 48</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug and had data for the outcome measure. Baseline values were carried forward for participants who discontinued therapy due to lack of efficacy.</population>
        <group_list>
          <group group_id="O1">
            <title>Doravirine 100 mg</title>
            <description>Double-blind Doravirine 100 mg administered orally (p.o.) once daily (q.d.) + investigator-selected TRUVADA™ or EPZICOM™/KIVEXA™ administered p.o., q.d. for 96 weeks in the Base Study.</description>
          </group>
          <group group_id="O2">
            <title>Daurunavir 800 mg + Ritonavir 100 mg</title>
            <description>Double-blind Darunavir 800 mg and Ritonavir 100 mg administered p.o., q.d. + investigator-selected TRUVADA™ or EPZICOM™/ KIVEXA™ administered p.o., q.d. for 96 weeks in the Base Study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean CD4+ T-cell Count at Week 48</title>
          <description>CD4+ T-cell counts were quantified by a central laboratory using a commercially available assay.</description>
          <population>All randomized participants who received at least 1 dose of study drug and had data for the outcome measure. Baseline values were carried forward for participants who discontinued therapy due to lack of efficacy.</population>
          <units>Cells/mm^3</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="363"/>
                <count group_id="O2" value="353"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="192.7" lower_limit="171.5" upper_limit="213.9"/>
                    <measurement group_id="O2" value="185.6" lower_limit="167.5" upper_limit="203.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Mean treatment difference</param_type>
            <param_value>7.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-20.8</ci_lower_limit>
            <ci_upper_limit>35.0</ci_upper_limit>
            <estimate_desc>Stratum-adjusted Mantel-Haenszel method with the difference weighted by the harmonic mean of sample size per arm for each stratum.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean CD4+ T-cell Count at Week 96</title>
        <description>CD4+ T-cell counts were quantified by a central laboratory using a commercially available assay.</description>
        <time_frame>Baseline and Week 96</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug and had data for the outcome measure. Baseline values were carried forward for participants who discontinued therapy due to lack of efficacy.</population>
        <group_list>
          <group group_id="O1">
            <title>Doravirine 100 mg</title>
            <description>Double-blind Doravirine 100 mg administered orally (p.o.) once daily (q.d.) + investigator-selected TRUVADA™ or EPZICOM™/KIVEXA™ administered p.o., q.d. for 96 weeks in the Base Study.</description>
          </group>
          <group group_id="O2">
            <title>Daurunavir 800 mg + Ritonavir 100 mg</title>
            <description>Double-blind Darunavir 800 mg and Ritonavir 100 mg administered p.o., q.d. + investigator-selected TRUVADA™ or EPZICOM™/ KIVEXA™ administered p.o., q.d. for 96 weeks in the Base Study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean CD4+ T-cell Count at Week 96</title>
          <description>CD4+ T-cell counts were quantified by a central laboratory using a commercially available assay.</description>
          <population>All randomized participants who received at least 1 dose of study drug and had data for the outcome measure. Baseline values were carried forward for participants who discontinued therapy due to lack of efficacy.</population>
          <units>Cells/mm^3</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="342"/>
                <count group_id="O2" value="327"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="224.1" lower_limit="200.8" upper_limit="247.4"/>
                    <measurement group_id="O2" value="206.7" lower_limit="184.9" upper_limit="228.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Mean treatment difference</param_type>
            <param_value>17.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.5</ci_lower_limit>
            <ci_upper_limit>49.3</ci_upper_limit>
            <estimate_desc>Stratum-adjusted Mantel-Haenszel method with the difference weighted by the harmonic mean of sample size per arm for each stratum.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) at Week 48</title>
        <description>Serum LDL-C was determined after an overnight fast. Change from Baseline was analyzed using ANCOVA models with terms for Baseline lipid level and treatment group. The Last Observation Carry Forward (LOCF) approach was applied for missing data or data collected after modifying lipid-lowering therapy.</description>
        <time_frame>Baseline and Week 48</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug and had a measurement at Baseline and at the time point assessed.</population>
        <group_list>
          <group group_id="O1">
            <title>Doravirine 100 mg</title>
            <description>Double-blind Doravirine 100 mg administered orally (p.o.) once daily (q.d.) + investigator-selected TRUVADA™ or EPZICOM™/KIVEXA™ administered p.o., q.d. for 96 weeks in the Base Study.</description>
          </group>
          <group group_id="O2">
            <title>Daurunavir 800 mg + Ritonavir 100 mg</title>
            <description>Double-blind Darunavir 800 mg and Ritonavir 100 mg administered p.o., q.d. + investigator-selected TRUVADA™ or EPZICOM™/ KIVEXA™ administered p.o., q.d. for 96 weeks in the Base Study.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) at Week 48</title>
          <description>Serum LDL-C was determined after an overnight fast. Change from Baseline was analyzed using ANCOVA models with terms for Baseline lipid level and treatment group. The Last Observation Carry Forward (LOCF) approach was applied for missing data or data collected after modifying lipid-lowering therapy.</description>
          <population>All randomized participants who received at least 1 dose of study drug and had a measurement at Baseline and at the time point assessed.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="326"/>
                <count group_id="O2" value="318"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.10" spread="28.61"/>
                    <measurement group_id="O2" value="91.76" spread="30.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.51" spread="20.64"/>
                    <measurement group_id="O2" value="9.92" spread="27.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Terms for Baseline lipid level and treatment group</method_desc>
            <param_type>Treatment Difference (mg/dL)</param_type>
            <param_value>-14.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.15</ci_lower_limit>
            <ci_upper_limit>-11.06</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Fasting Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 48</title>
        <description>Serum non-HDL-C was determined after an overnight fast. Change from Baseline was analyzed using ANCOVA models with terms for Baseline lipid level and treatment group. The LOCF approach was applied for missing data or data collected after modifying lipid-lowering therapy.</description>
        <time_frame>Baseline and Week 48</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug and had a measurement at Baseline and at the time point assessed.</population>
        <group_list>
          <group group_id="O1">
            <title>Doravirine 100 mg</title>
            <description>Double-blind Doravirine 100 mg administered orally (p.o.) once daily (q.d.) + investigator-selected TRUVADA™ or EPZICOM™/KIVEXA™ administered p.o., q.d. for 96 weeks in the Base Study.</description>
          </group>
          <group group_id="O2">
            <title>Daurunavir 800 mg + Ritonavir 100 mg</title>
            <description>Double-blind Darunavir 800 mg and Ritonavir 100 mg administered p.o., q.d. + investigator-selected TRUVADA™ or EPZICOM™/ KIVEXA™ administered p.o., q.d. for 96 weeks in the Base Study.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Fasting Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 48</title>
          <description>Serum non-HDL-C was determined after an overnight fast. Change from Baseline was analyzed using ANCOVA models with terms for Baseline lipid level and treatment group. The LOCF approach was applied for missing data or data collected after modifying lipid-lowering therapy.</description>
          <population>All randomized participants who received at least 1 dose of study drug and had a measurement at Baseline and at the time point assessed.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="329"/>
                <count group_id="O2" value="325"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113.34" spread="34.25"/>
                    <measurement group_id="O2" value="114.44" spread="35.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.30" spread="23.28"/>
                    <measurement group_id="O2" value="13.75" spread="31.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Terms for Baseline lipid level and treatment group</method_desc>
            <param_type>Treatment Difference (mg/dL)</param_type>
            <param_value>-19.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-23.33</ci_lower_limit>
            <ci_upper_limit>-15.35</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Fasting High Density Lipoprotein Cholesterol (HDL-C) at Week 48</title>
        <description>Serum HDL-C was determined after an overnight fast. Change from Baseline was analyzed using ANCOVA models with terms for Baseline lipid level and treatment group. The LOCF approach was applied for missing data or data collected after modifying lipid-lowering therapy.</description>
        <time_frame>Baseline and Week 48</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug and had a measurement at Baseline and at the time point assessed.</population>
        <group_list>
          <group group_id="O1">
            <title>Doravirine 100 mg</title>
            <description>Double-blind Doravirine 100 mg administered orally (p.o.) once daily (q.d.) + investigator-selected TRUVADA™ or EPZICOM™/KIVEXA™ administered p.o., q.d. for 96 weeks in the Base Study.</description>
          </group>
          <group group_id="O2">
            <title>Daurunavir 800 mg + Ritonavir 100 mg</title>
            <description>Double-blind Darunavir 800 mg and Ritonavir 100 mg administered p.o., q.d. + investigator-selected TRUVADA™ or EPZICOM™/ KIVEXA™ administered p.o., q.d. for 96 weeks in the Base Study.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Fasting High Density Lipoprotein Cholesterol (HDL-C) at Week 48</title>
          <description>Serum HDL-C was determined after an overnight fast. Change from Baseline was analyzed using ANCOVA models with terms for Baseline lipid level and treatment group. The LOCF approach was applied for missing data or data collected after modifying lipid-lowering therapy.</description>
          <population>All randomized participants who received at least 1 dose of study drug and had a measurement at Baseline and at the time point assessed.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="329"/>
                <count group_id="O2" value="325"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.58" spread="12.99"/>
                    <measurement group_id="O2" value="43.27" spread="13.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.94" spread="10.66"/>
                    <measurement group_id="O2" value="4.15" spread="11.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Fasting Total Cholesterol at Week 48</title>
        <description>Serum total cholesterol was determined after an overnight fast. Change from Baseline was analyzed using ANCOVA models with terms for Baseline lipid level and treatment group. The LOCF approach was applied for missing data or data collected after modifying lipid-lowering therapy.</description>
        <time_frame>Baseline and Week 48</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug and had a measurement at Baseline and at the time point assessed.</population>
        <group_list>
          <group group_id="O1">
            <title>Doravirine 100 mg</title>
            <description>Double-blind Doravirine 100 mg administered orally (p.o.) once daily (q.d.) + investigator-selected TRUVADA™ or EPZICOM™/KIVEXA™ administered p.o., q.d. for 96 weeks in the Base Study.</description>
          </group>
          <group group_id="O2">
            <title>Daurunavir 800 mg + Ritonavir 100 mg</title>
            <description>Double-blind Darunavir 800 mg and Ritonavir 100 mg administered p.o., q.d. + investigator-selected TRUVADA™ or EPZICOM™/ KIVEXA™ administered p.o., q.d. for 96 weeks in the Base Study.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Fasting Total Cholesterol at Week 48</title>
          <description>Serum total cholesterol was determined after an overnight fast. Change from Baseline was analyzed using ANCOVA models with terms for Baseline lipid level and treatment group. The LOCF approach was applied for missing data or data collected after modifying lipid-lowering therapy.</description>
          <population>All randomized participants who received at least 1 dose of study drug and had a measurement at Baseline and at the time point assessed.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="329"/>
                <count group_id="O2" value="325"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="156.92" spread="35.82"/>
                    <measurement group_id="O2" value="157.71" spread="37.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.37" spread="25.47"/>
                    <measurement group_id="O2" value="17.90" spread="33.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Fasting Triglyceride at Week 48</title>
        <description>Serum triglyceride was determined after an overnight fast. Change from Baseline was analyzed using ANCOVA models with terms for Baseline lipid level and treatment group. The LOCF approach was applied for missing data or data collected after modifying lipid-lowering therapy.</description>
        <time_frame>Baseline and Week 48</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug and had a measurement at Baseline and at the time point assessed.</population>
        <group_list>
          <group group_id="O1">
            <title>Doravirine 100 mg</title>
            <description>Double-blind Doravirine 100 mg administered orally (p.o.) once daily (q.d.) + investigator-selected TRUVADA™ or EPZICOM™/KIVEXA™ administered p.o., q.d. for 96 weeks in the Base Study.</description>
          </group>
          <group group_id="O2">
            <title>Daurunavir 800 mg + Ritonavir 100 mg</title>
            <description>Double-blind Darunavir 800 mg and Ritonavir 100 mg administered p.o., q.d. + investigator-selected TRUVADA™ or EPZICOM™/ KIVEXA™ administered p.o., q.d. for 96 weeks in the Base Study.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Fasting Triglyceride at Week 48</title>
          <description>Serum triglyceride was determined after an overnight fast. Change from Baseline was analyzed using ANCOVA models with terms for Baseline lipid level and treatment group. The LOCF approach was applied for missing data or data collected after modifying lipid-lowering therapy.</description>
          <population>All randomized participants who received at least 1 dose of study drug and had a measurement at Baseline and at the time point assessed.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="329"/>
                <count group_id="O2" value="325"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111.16" spread="75.31"/>
                    <measurement group_id="O2" value="117.02" spread="97.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.14" spread="68.81"/>
                    <measurement group_id="O2" value="21.97" spread="92.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Any Adverse Event</title>
        <description>An adverse event (AE) is defined as any untoward medical occurrence in a study participant and which does not necessarily have to have a causal relationship to treatment. An adverse event can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the study treatment or protocol-specified procedure, whether or not considered related to study treatment or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the study treatment is also an AE. The percentage of participants with any AE was assessed.</description>
        <time_frame>Up to 98 weeks</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Doravirine 100 mg</title>
            <description>Double-blind Doravirine 100 mg administered orally (p.o.) once daily (q.d.) + investigator-selected TRUVADA™ or EPZICOM™/KIVEXA™ administered p.o., q.d. for 96 weeks in the Base Study.</description>
          </group>
          <group group_id="O2">
            <title>Daurunavir 800 mg + Ritonavir 100 mg</title>
            <description>Double-blind Darunavir 800 mg and Ritonavir 100 mg administered p.o., q.d. + investigator-selected TRUVADA™ or EPZICOM™/ KIVEXA™ administered p.o., q.d. for 96 weeks in the Base Study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Any Adverse Event</title>
          <description>An adverse event (AE) is defined as any untoward medical occurrence in a study participant and which does not necessarily have to have a causal relationship to treatment. An adverse event can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the study treatment or protocol-specified procedure, whether or not considered related to study treatment or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the study treatment is also an AE. The percentage of participants with any AE was assessed.</description>
          <population>All randomized participants who received at least 1 dose of study drug</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="383"/>
                <count group_id="O2" value="383"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.6"/>
                    <measurement group_id="O2" value="82.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Any Serious Adverse Event</title>
        <description>A serious adverse event is an AE that results in death, is life threatening, results in persistent or significant disability or incapacity, results in or prolongs a hospitalization, is a congenital anomaly or birth defect, is a cancer, is associated with an overdose, or is another important medical event. The percentage of participants with any SAE was assessed.</description>
        <time_frame>Up to 98 weeks</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Doravirine 100 mg</title>
            <description>Double-blind Doravirine 100 mg administered orally (p.o.) once daily (q.d.) + investigator-selected TRUVADA™ or EPZICOM™/KIVEXA™ administered p.o., q.d. for 96 weeks in the Base Study.</description>
          </group>
          <group group_id="O2">
            <title>Daurunavir 800 mg + Ritonavir 100 mg</title>
            <description>Double-blind Darunavir 800 mg and Ritonavir 100 mg administered p.o., q.d. + investigator-selected TRUVADA™ or EPZICOM™/ KIVEXA™ administered p.o., q.d. for 96 weeks in the Base Study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Any Serious Adverse Event</title>
          <description>A serious adverse event is an AE that results in death, is life threatening, results in persistent or significant disability or incapacity, results in or prolongs a hospitalization, is a congenital anomaly or birth defect, is a cancer, is associated with an overdose, or is another important medical event. The percentage of participants with any SAE was assessed.</description>
          <population>All randomized participants who received at least 1 dose of study drug</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="383"/>
                <count group_id="O2" value="383"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0"/>
                    <measurement group_id="O2" value="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Any Drug-related Adverse Event</title>
        <description>The investigator was to determine if an AE had a reasonable possibility of a relationship to the study drug. The percentage of participants with any drug-related AE was assessed.</description>
        <time_frame>Up to 98 weeks</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Doravirine 100 mg</title>
            <description>Double-blind Doravirine 100 mg administered orally (p.o.) once daily (q.d.) + investigator-selected TRUVADA™ or EPZICOM™/KIVEXA™ administered p.o., q.d. for 96 weeks in the Base Study.</description>
          </group>
          <group group_id="O2">
            <title>Daurunavir 800 mg + Ritonavir 100 mg</title>
            <description>Double-blind Darunavir 800 mg and Ritonavir 100 mg administered p.o., q.d. + investigator-selected TRUVADA™ or EPZICOM™/ KIVEXA™ administered p.o., q.d. for 96 weeks in the Base Study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Any Drug-related Adverse Event</title>
          <description>The investigator was to determine if an AE had a reasonable possibility of a relationship to the study drug. The percentage of participants with any drug-related AE was assessed.</description>
          <population>All randomized participants who received at least 1 dose of study drug</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="383"/>
                <count group_id="O2" value="383"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.1"/>
                    <measurement group_id="O2" value="32.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Any Drug-related Serious Adverse Event</title>
        <description>The percentage of participants with any drug-related SAE was assessed.</description>
        <time_frame>Up to 98 weeks</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Doravirine 100 mg</title>
            <description>Double-blind Doravirine 100 mg administered orally (p.o.) once daily (q.d.) + investigator-selected TRUVADA™ or EPZICOM™/KIVEXA™ administered p.o., q.d. for 96 weeks in the Base Study.</description>
          </group>
          <group group_id="O2">
            <title>Daurunavir 800 mg + Ritonavir 100 mg</title>
            <description>Double-blind Darunavir 800 mg and Ritonavir 100 mg administered p.o., q.d. + investigator-selected TRUVADA™ or EPZICOM™/ KIVEXA™ administered p.o., q.d. for 96 weeks in the Base Study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Any Drug-related Serious Adverse Event</title>
          <description>The percentage of participants with any drug-related SAE was assessed.</description>
          <population>All randomized participants who received at least 1 dose of study drug</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="383"/>
                <count group_id="O2" value="383"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3"/>
                    <measurement group_id="O2" value="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Discontinued Study Treatment Due to an Adverse Event</title>
        <description>The percentage of participants who discontinued study treatment due to an AE was assessed.</description>
        <time_frame>Up to 96 weeks</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Doravirine 100 mg</title>
            <description>Double-blind Doravirine 100 mg administered orally (p.o.) once daily (q.d.) + investigator-selected TRUVADA™ or EPZICOM™/KIVEXA™ administered p.o., q.d. for 96 weeks in the Base Study.</description>
          </group>
          <group group_id="O2">
            <title>Daurunavir 800 mg + Ritonavir 100 mg</title>
            <description>Double-blind Darunavir 800 mg and Ritonavir 100 mg administered p.o., q.d. + investigator-selected TRUVADA™ or EPZICOM™/ KIVEXA™ administered p.o., q.d. for 96 weeks in the Base Study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Discontinued Study Treatment Due to an Adverse Event</title>
          <description>The percentage of participants who discontinued study treatment due to an AE was assessed.</description>
          <population>All randomized participants who received at least 1 dose of study drug</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="383"/>
                <count group_id="O2" value="383"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Plasma HIV-1 RNA &lt;40 Copies/mL at Week 48</title>
        <description>The percentage of participants in each arm achieving HIV-1 RNA levels &lt;40 copies/mL at Week 48 was determined. Plasma HIV-1 RNA levels were quantified with the Abbott RealTime HIV-1 Assay. Data were handled according to the US Food and Drug Administration (FDA) &quot;snapshot&quot; approach and all missing data were considered treatment failures, regardless of the reason.</description>
        <time_frame>Week 48</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Doravirine 100 mg</title>
            <description>Double-blind Doravirine 100 mg administered orally (p.o.) once daily (q.d.) + investigator-selected TRUVADA™ or EPZICOM™/KIVEXA™ administered p.o., q.d. for 96 weeks in the Base Study.</description>
          </group>
          <group group_id="O2">
            <title>Daurunavir 800 mg + Ritonavir 100 mg</title>
            <description>Double-blind Darunavir 800 mg and Ritonavir 100 mg administered p.o., q.d. + investigator-selected TRUVADA™ or EPZICOM™/ KIVEXA™ administered p.o., q.d. for 96 weeks in the Base Study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Plasma HIV-1 RNA &lt;40 Copies/mL at Week 48</title>
          <description>The percentage of participants in each arm achieving HIV-1 RNA levels &lt;40 copies/mL at Week 48 was determined. Plasma HIV-1 RNA levels were quantified with the Abbott RealTime HIV-1 Assay. Data were handled according to the US Food and Drug Administration (FDA) &quot;snapshot&quot; approach and all missing data were considered treatment failures, regardless of the reason.</description>
          <population>All randomized participants who received at least 1 dose of study drug</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="383"/>
                <count group_id="O2" value="383"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.3"/>
                    <measurement group_id="O2" value="79.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Treatment Difference</param_type>
            <param_value>4.169</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.404</ci_lower_limit>
            <ci_upper_limit>9.743</ci_upper_limit>
            <estimate_desc>Stratum-adjusted Mantel-Haenszel method with the difference weighted by the harmonic mean of sample size per arm for each stratum.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Plasma HIV-1 RNA &lt;40 Copies/mL at Week 96</title>
        <description>The percentage of participants in each arm achieving HIV-1 RNA levels &lt;40 copies/mL at Week 96 was determined. Plasma HIV-1 RNA levels were quantified with the Abbott RealTime HIV-1 Assay. Data were handled according to the US Food and Drug Administration (FDA) &quot;snapshot&quot; approach and all missing data were considered treatment failures, regardless of the reason.</description>
        <time_frame>Week 96</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug and had data for the outcome measure. Participants with missing HIV-1 RNA due to an Abbott RealTime manufacturing agent recall were excluded from the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Doravirine 100 mg</title>
            <description>Double-blind Doravirine 100 mg administered orally (p.o.) once daily (q.d.) + investigator-selected TRUVADA™ or EPZICOM™/KIVEXA™ administered p.o., q.d. for 96 weeks in the Base Study.</description>
          </group>
          <group group_id="O2">
            <title>Daurunavir 800 mg + Ritonavir 100 mg</title>
            <description>Double-blind Darunavir 800 mg and Ritonavir 100 mg administered p.o., q.d. + investigator-selected TRUVADA™ or EPZICOM™/ KIVEXA™ administered p.o., q.d. for 96 weeks in the Base Study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Plasma HIV-1 RNA &lt;40 Copies/mL at Week 96</title>
          <description>The percentage of participants in each arm achieving HIV-1 RNA levels &lt;40 copies/mL at Week 96 was determined. Plasma HIV-1 RNA levels were quantified with the Abbott RealTime HIV-1 Assay. Data were handled according to the US Food and Drug Administration (FDA) &quot;snapshot&quot; approach and all missing data were considered treatment failures, regardless of the reason.</description>
          <population>All randomized participants who received at least 1 dose of study drug and had data for the outcome measure. Participants with missing HIV-1 RNA due to an Abbott RealTime manufacturing agent recall were excluded from the analysis.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="379"/>
                <count group_id="O2" value="376"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.0"/>
                    <measurement group_id="O2" value="64.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Treatment Difference</param_type>
            <param_value>7.606</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.980</ci_lower_limit>
            <ci_upper_limit>14.232</ci_upper_limit>
            <estimate_desc>Stratum-adjusted Mantel-Haenszel method with the difference weighted by the harmonic mean of sample size per arm for each stratum.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to Week 98</time_frame>
      <desc>The at-risk population is all participants who received at least 1 dose of study drug</desc>
      <group_list>
        <group group_id="E1">
          <title>Doravirine 100 mg</title>
          <description>Double-blind Doravirine 100 mg administered orally (p.o.) once daily (q.d.) + investigator-selected TRUVADA™ or EPZICOM™/KIVEXA™ administered p.o., q.d. for 96 weeks in the Base Study.</description>
        </group>
        <group group_id="E2">
          <title>Daurunavir 800 mg + Ritonavir 100 mg</title>
          <description>Double-blind Darunavir 800 mg and Ritonavir 100 mg administered p.o., q.d. + investigator-selected TRUVADA™ or EPZICOM™/ KIVEXA™ administered p.o., q.d. for 96 weeks in the Base Study.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Anal skin tags</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" events="5" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Acute hepatitis C</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Atypical pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Cellulitis staphylococcal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Meningitis tuberculous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Necrotising fasciitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Neurosyphilis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Parotitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Perirectal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Scrotal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Tuberculosis of central nervous system</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Carbon monoxide poisoning</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Rectal injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Traumatic intracranial haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Anal squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Facial paralysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Osmotic demyelination syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Post abortion haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Schizoaffective disorder depressive type</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Substance-induced mood disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Stridor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Drug abuser</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="228" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="216" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="23" subjects_affected="20" subjects_at_risk="383"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="74" subjects_affected="65" subjects_at_risk="383"/>
                <counts group_id="E2" events="120" subjects_affected="91" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="53" subjects_affected="44" subjects_at_risk="383"/>
                <counts group_id="E2" events="59" subjects_affected="52" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="36" subjects_affected="34" subjects_at_risk="383"/>
                <counts group_id="E2" events="25" subjects_affected="23" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="27" subjects_affected="23" subjects_at_risk="383"/>
                <counts group_id="E2" events="30" subjects_affected="28" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Syphilis</sub_title>
                <counts group_id="E1" events="27" subjects_affected="22" subjects_at_risk="383"/>
                <counts group_id="E2" events="26" subjects_affected="23" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="74" subjects_affected="51" subjects_at_risk="383"/>
                <counts group_id="E2" events="43" subjects_affected="30" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="61" subjects_affected="44" subjects_at_risk="383"/>
                <counts group_id="E2" events="70" subjects_affected="50" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="29" subjects_affected="28" subjects_at_risk="383"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="23" subjects_affected="20" subjects_at_risk="383"/>
                <counts group_id="E2" events="20" subjects_affected="19" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="86" subjects_affected="57" subjects_at_risk="383"/>
                <counts group_id="E2" events="68" subjects_affected="46" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="383"/>
                <counts group_id="E2" events="22" subjects_affected="20" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="28" subjects_affected="23" subjects_at_risk="383"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

